Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA056-015  |   NCT05664737

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia

Resumen

  • Phase 2
  • Ícono de género masculino y femenino
  • 12+
  • 4
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The purpose of the study is to determine the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in participants with α-thalassemia hemoglobin H (HbH) disease.

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Key Inclusion Criteria: - Participant has documented diagnosis of α-thalassemia hemoglobin H (HbH) disease (electrophoresis⎯ or high-performance liquid chromatography [HPLC]⎯based methods for Hb variant analyses are accepted), with or without transfusion dependence; compounded combination with β-thalassemia is allowed if at least 1 non-mutated β-chain gene is present. TD: i) TD participant: (1) ≥ 6 RBC units during the 24 weeks prior to randomization; and (2) No transfusion-free period for > 56 days during the 24 weeks prior to randomization; ii) NTD participant: (1) < 6 Red blood cell (RBC) units during the 24 weeks prior to randomization; and (2) RBC transfusion-free during at least 8 weeks prior to randomization; and (3) Mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values within 21 days post-transfusion will be excluded. - Participant has Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. - Investigators shall counsel women of childbearing potential (WOCBP), and male participants who are sexually active with WOCBP, on the importance of pregnancy prevention, the implications of an unexpected pregnancy, and the potential of fetal toxicity occurring due to transmission of study intervention, present in seminal fluid, to a developing fetus, even if the participant has undergone a successful vasectomy or if the partner is pregnant. Key Exclusion Criteria: - Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. - Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study - History of deep venous thrombosis (DVT) or stroke requiring medical intervention ≤ 24 weeks prior to randomization - Diagnosis of α-thalassemia Trait, Hb Bart hydrops, ATRx α-thalassemia, hemoglobin S/β-thalassemia, myelodysplasia subtype anemia, or with HbE homozygous beta gene mutation. - Anemia related to nutritional deficiency, anemia of chronic disease, autoimmune hemolytic anemia, or any other hemolytic anemias (for example, severe G6PD deficiency, pyruvate kinase deficiency, etc.). - Bleeding disorders manifested by frequent bleeding episodes (e.g., menorrhagia, epistaxis, clotting disorders). - Undergone episodes of hemolysis not related to alpha-thalassemia, for example, after use of hemolysis-predisposing drugs (for example, antimalarial, nonsteroidal anti-inflammatory drug [NSAID]), within the 8 weeks prior to randomization. - Prior exposure to gene therapy to treat α-thalassemia. - Use of an erythropoiesis-stimulating agent (ESA) ≤ 24 weeks prior to randomization. Note: Other protocol-defined inclusion/exclusion criteria apply.

Opciones de tratamiento

Brazos del estudio

INTERVENCIÓN ASIGNADA

Brazos del estudio

Experimental: Non-transfusion Dependent (NTD): Luspatercept + BSC

INTERVENCIÓN ASIGNADA
  • Biological: Luspatercept

Brazos del estudio

Placebo Comparator: NTD: Placebo + BSC

INTERVENCIÓN ASIGNADA
  • Drug: Placebo

Brazos del estudio

Placebo Comparator: TD: Placebo + BSC

INTERVENCIÓN ASIGNADA
  • Drug: Placebo

Brazos del estudio

Experimental: Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)

INTERVENCIÓN ASIGNADA
  • Biological: Luspatercept
Seleccione un centro del estudio para registrarse
Seleccione una ubicación del centro del estudio
Seleccione una ubicación del centro del estudio que sea conveniente para usted
Registrarse
Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias